pharma · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · metastatic or unresectable, recurrent HNSCC
Createrna Science and
Wuhan Createrna Science and Technology Co., Ltd
Wuhan Createrna Science is a pharma organization headquartered in London, GB. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, metastatic or unresectable, recurrent HNSCC,
Company details
- Status
- Public
- HQ
- shanghai, CN, London
- Employees
- 26
- Programs
- 51
- Drugs
- 87
- Patents
- 0
SELPERCATINIB, SELPERCATINIB
Phase 2 · small molecule · Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.
SELPERCATINIB, SELPERCATINIB for Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood. is a Phase 2 program (small_molecule) at Wuhan Createrna Science and Technology Co., Ltd with 1 ClinicalTrials.gov record(s).
Internal code LOXO-RET-17001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.
- Status
- active
- Trials
- 1